Cardiovascular disease (CVD) remains a major cause of premature mortality and rising health care costs. Cardiometabolic, behavioral, environmental, and social risk factors are major drivers of CVD. Emergency and critical care physician face cardiovascular disease patients with rapidly changing conditions, which require accurate risk stratification and initiation of suitable treatments. It presents a constant challenge worldwide.
Coronavirus Disease 2019 (COVID-19) originated in Wuhan, China in December 2019 and rapidly spread worldwide. COVID-19 has been associated with myocardial injury in up to 40% of hospitalized cases, myocarditis, cardiac arrhythmias, acute coronary syndrome, and sudden cardiac death (SCD) and may coexist with many comorbidities, including chronic heart failure. The likelihood of survival may vary significantly among patients with different etiologies of heart failure and subsets of individuals with cardiovascular diseases.
In the 21st century, Chagas disease is still a major health problem in Latin America, where about 6 million people are carriers of the disease, and about 10,000 people die of such illness annually. Moreover, cases of Chagas disease are now found globally; estimates suggest over 300,000 immigrants with this condition living in the USA, Canada, and Europe. Importantly, recent studies evidenced that chronic heart failure secondary to Chagas Cardiomyopathy has a poorer prognosis than that observed in other etiologies.
For these reasons, in addition to basic support, cardiac reactions of patients with confirmed or suspected COVID-19 with underlying cardiovascular diseases should be closely monitored.
The aim of this Research Topic is to collect manuscripts which will help in spreading light on the best management of cardiovascular disease patients with confirmed or suspected COVID-19 in emergency or critical care settings. In particular, this Research Topic primarily focuses on a large population with cardiovascular disease living in area where Chagas Disease is endemic.
We welcome submissions of Original Research, Systematic Review, Study Protocol, Case Report, and Review Articles. The topics of interest include but are not limited to the following:
• Predictive models for risk stratification of emergency and critical ill patients with cardiovascular diseases.
• Emergency and critical management of patients with Chagas Disease and COVID-19.
• Understanding of social and economic burden of the cardiovascular diseases associated to COVID-19 in low and middle-income countries.
• Critical implications of the current pandemic for patients with Chagas heart failure.
• Chagas Disease reactivation due to glucocorticoid therapy in patients with chronic Chagas Disease and COVID-19, as seen in patients with silent strongyloidiasis.
• Prevention of thromboembolic phenomena in patients with chronic Chagas Disease and COVID-19.
• Effects of COVID-19 on patients with chronic Chagas disease and complex ventricular arrhythmias.
Cardiovascular disease (CVD) remains a major cause of premature mortality and rising health care costs. Cardiometabolic, behavioral, environmental, and social risk factors are major drivers of CVD. Emergency and critical care physician face cardiovascular disease patients with rapidly changing conditions, which require accurate risk stratification and initiation of suitable treatments. It presents a constant challenge worldwide.
Coronavirus Disease 2019 (COVID-19) originated in Wuhan, China in December 2019 and rapidly spread worldwide. COVID-19 has been associated with myocardial injury in up to 40% of hospitalized cases, myocarditis, cardiac arrhythmias, acute coronary syndrome, and sudden cardiac death (SCD) and may coexist with many comorbidities, including chronic heart failure. The likelihood of survival may vary significantly among patients with different etiologies of heart failure and subsets of individuals with cardiovascular diseases.
In the 21st century, Chagas disease is still a major health problem in Latin America, where about 6 million people are carriers of the disease, and about 10,000 people die of such illness annually. Moreover, cases of Chagas disease are now found globally; estimates suggest over 300,000 immigrants with this condition living in the USA, Canada, and Europe. Importantly, recent studies evidenced that chronic heart failure secondary to Chagas Cardiomyopathy has a poorer prognosis than that observed in other etiologies.
For these reasons, in addition to basic support, cardiac reactions of patients with confirmed or suspected COVID-19 with underlying cardiovascular diseases should be closely monitored.
The aim of this Research Topic is to collect manuscripts which will help in spreading light on the best management of cardiovascular disease patients with confirmed or suspected COVID-19 in emergency or critical care settings. In particular, this Research Topic primarily focuses on a large population with cardiovascular disease living in area where Chagas Disease is endemic.
We welcome submissions of Original Research, Systematic Review, Study Protocol, Case Report, and Review Articles. The topics of interest include but are not limited to the following:
• Predictive models for risk stratification of emergency and critical ill patients with cardiovascular diseases.
• Emergency and critical management of patients with Chagas Disease and COVID-19.
• Understanding of social and economic burden of the cardiovascular diseases associated to COVID-19 in low and middle-income countries.
• Critical implications of the current pandemic for patients with Chagas heart failure.
• Chagas Disease reactivation due to glucocorticoid therapy in patients with chronic Chagas Disease and COVID-19, as seen in patients with silent strongyloidiasis.
• Prevention of thromboembolic phenomena in patients with chronic Chagas Disease and COVID-19.
• Effects of COVID-19 on patients with chronic Chagas disease and complex ventricular arrhythmias.